Published in J Clin Gastroenterol on April 01, 2010
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ (2013) 1.74
Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol (2012) 1.00
Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharm (2012) 0.97
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol (2013) 0.84
Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol (2012) 0.82
Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori. Med J Islam Repub Iran (2015) 0.80
Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther (2015) 0.80
Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus. World J Gastroenterol (2014) 0.78
Sequential therapy for Helicobacter pylori infection: ethical considerations revisited. J Clin Gastroenterol (2010) 0.78
Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. World J Gastroenterol (2014) 0.77
Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol (2015) 0.77
Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract (2016) 0.75
A new paradigm for clinical trials in antibiotherapy? Can J Infect Dis Med Microbiol (2011) 0.75
Evaluation of the benefit of addition of clidinium C to a Helicobacter pylori eradication regimen. Gastroenterol Hepatol Bed Bench (2013) 0.75
Morphologic and pharmacological investigations in the epicatechin gastroprotective effect. Evid Based Complement Alternat Med (2012) 0.75
Comparison of amoxicillin and metronidazole effect on three-drug regimen for the treatment of Helicobacter pylori infection in children. J Adv Pharm Technol Res (2017) 0.75
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology (2008) 2.38
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92
Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2008) 1.88
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
Effective bowel cleansing before colonoscopy: a randomized study of split-dosage versus non-split dosage regimens of high-volume versus low-volume polyethylene glycol solutions. Gastrointest Endosc (2010) 1.77
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology (2002) 1.58
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem (2003) 1.54
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol (2008) 1.53
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. J Crohns Colitis (2011) 1.52
IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol (2007) 1.49
Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc (2006) 1.46
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets (2008) 1.43
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease. J Crohns Colitis (2012) 1.40
Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol (2006) 1.40
Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol (2010) 1.40
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2006) 1.38
Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol (2008) 1.35
Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol (2008) 1.33
Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol (2004) 1.32
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med (2011) 1.27
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology (2009) 1.19
Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm Bowel Dis (2009) 1.18
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology (2006) 1.17
Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol (2011) 1.16
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis (2007) 1.15
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology (2005) 1.14
Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir. Hepatology (2014) 1.14
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther (2012) 1.13
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.12
New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol (2006) 1.11
Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm (2009) 1.10
Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology (2002) 1.09
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol (2007) 1.08
The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol (2012) 1.07
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol (2007) 1.06
Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol (2006) 1.06
Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol (2011) 1.04
Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol (2006) 1.04
Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med (2011) 1.03
Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev (2009) 1.03
Aryl hydrocarbon receptor and colitis. Semin Immunopathol (2013) 1.02
Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection. Gastroenterology (2004) 1.02
Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED Score and Prospective Comparison with the Rockall Score. Am J Gastroenterol (2010) 1.02
The dual role of inflammation in colon carcinogenesis. Int J Mol Sci (2012) 1.01
Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci (2009) 1.00
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood (2009) 0.99
Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol (2007) 0.99
Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol (2010) 0.98
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroenterol (2009) 0.98
Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells. Infect Immun (2004) 0.98
Interleukin-25: a two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev (2010) 0.98
IL-21 promotes skin recruitment of CD4(+) cells and drives IFN-γ-dependent epidermal hyperplasia. J Immunol (2011) 0.95
Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS One (2013) 0.94
Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res (2011) 0.93
Appropriateness of the indication for colonoscopy: is the endoscopist the 'gold standard'? J Clin Gastroenterol (2012) 0.93
Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease. World J Gastroenterol (2010) 0.92
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflamm Bowel Dis (2011) 0.92
Targeting interleukin-21 in inflammatory diseases. Expert Opin Ther Targets (2011) 0.92
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci (2013) 0.92
TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis (2012) 0.91
Molecular targets of TRAIL-sensitizing agents in colorectal cancer. Int J Mol Sci (2012) 0.91
Conservative treatment of anastomotic leakage following low anterior resection. Am J Gastroenterol (2008) 0.91
Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population. J Invest Dermatol (2004) 0.90
Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population. Eur J Dermatol (2002) 0.90
IL-21 as a therapeutic target in inflammatory disorders. Expert Opin Ther Targets (2014) 0.89
Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis (2011) 0.89
Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci (Lond) (2011) 0.89
99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging (2003) 0.89
Measuring disease activity in Crohn's disease. Abdom Imaging (2012) 0.88
Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease. J Crohns Colitis (2012) 0.88
The dual role of Smad7 in the control of cancer growth and metastasis. Int J Mol Sci (2013) 0.88
Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol (2007) 0.88
Look out before polypectomy in patients with diverticular disease--a case of a large, inverted diverticulum of the colon resembling a pedunculated polyp. Can J Gastroenterol (2010) 0.87
Analysis of the cytokine profile in the duodenal mucosa of refractory coeliac disease patients. Clin Sci (Lond) (2014) 0.87
Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions. Am J Pathol (2003) 0.87
Interleukin-12 drives the Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa. Infect Immun (2007) 0.87
Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. Infect Immun (2007) 0.87
Interleukin-21 in chronic inflammatory diseases. Biofactors (2013) 0.87
Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease. PLoS One (2013) 0.86
Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad. Int Rev Immunol (2013) 0.86
TGF-Beta signaling manipulation as potential therapy for IBD. Curr Drug Targets (2013) 0.85
ATG16L1 Ala197Thr is not associated with susceptibility to Crohn's disease or with phenotype in an Italian population. Gastroenterology (2008) 0.85
Bacteria and mucosal immunity. Dig Liver Dis (2006) 0.85
Interleukin-21 (IL-21) controls inflammatory pathways in the gut. Endocr Metab Immune Disord Drug Targets (2007) 0.85